Zonal distribution of AHR mRNA and ARNT mRNA and the effect of treatment with 3MC, βNF or omeprazole
| Treatment | AHR | ARNT | ||||||
|---|---|---|---|---|---|---|---|---|
| (n) | pp | pv | pv/pp | (n) | pp | pv | pv/pp | |
| Series 1 | ||||||||
| Control | (5) | 60 ± 12 | 203 ± 13* | 3.5 | (4) | 183 ± 68 | 147 ± 52 | 0.8 |
| 3MC | (5) | 151 ± 50b | 505 ± 95c * | 3.7 | (3) | 351 ± 18b | 318 ± 361-a | 0.9 |
| βNF | (5) | 122 ± 421-a | 388 ± 90b | 3.3 | (3) | 128 ± 53 | 252 ± 92 | 2.0 |
| Series 21-d | ||||||||
| Control | (4) | 0.13 ± 0.07 | 0.75 ± 0.28** | 6.3 | (4) | 0.19 ± 0.13 | 0.28 ± 0.12* | 1.9 |
| OME | (6) | 0.11 ± 0.03 | 0.90 ± 0.37*** | 8.9 | (6) | 0.14 ± 0.05 | 0.27 ± 0.09 | 2.3 |
RT-PCR products of AHR mRNA or ARNT mRNA from periportal (pp) and perivenous (pv) liver eluates obtained from rats pretreated with 3MC, βNF, omeprazole (OME) or vehicle only (control) were quantified by HPLC as described under “Methods.” Mean values of normalized peak areas ± S.D. with the number of experiments in parentheses are shown. The mean of the ratio between the amplified product of the corresponding perivenous and periportal sample is given in the last column.